Immunomodulatory Properties of Polysaccharides from Lentinula edodes

Aleksander Roszczyk 1, Jadwiga Turło 2, Radosław Zagoźdzon 1 and Beata Kaleta 1,*

1 Department of Clinical Immunology, Medical University of Warsaw, Nowogrodzka 59, 02-006 Warsaw, Poland
2 Department of Drug Technology and Pharmaceutical Biotechnology, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
* Correspondence: beata.kaleta@wum.edu.pl; Tel.: +48-600301690

Abstract: Lentinula edodes (Berk.) Pegler, also known as shiitake mushroom, is a popular edible macrofungus and a source of numerous bioactive substances with multiple beneficial health effects. L. edodes-derived polysaccharides are the most valuable compounds, with anticancer, antioxidant, antimicrobial, and immunomodulatory properties. It has been demonstrated that their biological activity depends on the extraction method, which affects monosaccharide composition, molecular weight, branching degrees, and helical conformation. In this review, we discuss the immunomodulatory properties of various polysaccharides from L. edodes in animal models and in humans.

Keywords: immunomodulation; Lentinula edodes; polysaccharide

1. Introduction

Lentinula edodes (Berk.) Pegler, also known as shiitake mushroom, is the most popular edible macrofungus, belonging to the Basidiomycota [1]. L. edodes grows naturally in the humid and warm regions of North and South America, Asia, and Australia and is also widely cultivated all over the world [2]. Numerous studies have demonstrated that L. edodes fruiting bodies and mycelium are a source of various nutrients and bioactive substances with multiple beneficial health effects [2,3]. L. edodes contains about 68–78% of carbohydrates (mono-, di-, tri-, and polysaccharides), exogenous amino acids (including arginine, histidine, leucine, isoleucine, lysine, methionine, phenylalanine, threonine, valine, and tryptophan), lipids (5–8% of dry matter), vitamins (including B1, B2, B12, C, D, E), minerals (including Ca, K, Mg, Mn, P, Zn, and Na), fiber, and numerous substances with antibacterial, antiviral, and antifungal properties [3,4]. The main compounds of L. edodes are presented in Figure 1. L. edodes-derived polysaccharides are widely studied and the most valuable compounds with proven anticancer, antioxidant, antiaging, antimicrobial, and immunomodulatory properties [5,6]. Studies on the mechanism of the immunomodulatory action of fungal polysaccharides suggested that it is a complex interaction between immunological, metabolic, and epigenetic changes [7]. As detailed below, β-glucans are the main polysaccharides found in the fungal cell wall and are responsible for most of the biological effects. Glucan molecules are considered to be pathogen-associated molecular patterns (PAMPs) and various pattern-recognition receptors (PRRs) can recognize them (please see below for details) [7,8].

It is worth emphasizing that besides polysaccharides, other L. edodes compounds are biologically active [5,6]. Findings from recent studies indicated that exogenous amino acids regulate cytokines and nitric oxide (NO) synthesis, antibodies production, and lymphocytes proliferation [3]. In addition, evidence of B and D vitamins role in the immune response has accumulated in past years. It has been demonstrated that B vitamins regulate the function of T helper (Th) cells, natural killer (NK) cells, and macrophages, including cells proliferation, cytokines synthesis, and NO production. Vitamin D also regulates the function of all immune cells, including T and B lymphocytes, monocytes/macrophages, and dendritic...
cells. Minerals present in *L. edodes*, particularly Mg and Zn, are essential for the innate and adaptive immune response. They regulate the function of macrophages, neutrophils, T and B lymphocytes, as well as NK cells [4].

It has been demonstrated that cultivation and extraction method are essential steps in obtaining polysaccharides because they affect their monosaccharide composition, different molecular weight, branching degrees, helical conformation, as well as biological activity [7,8].

![Diagram of polysaccharides and their properties](image)

**Figure 1.** Main active compounds of *Lentinula edodes*.

In this review, we discuss immunomodulatory properties of polysaccharides from *L. edodes* in animal models and in humans.

2. Polysaccharides from *L. edodes*—Immunomodulatory Properties

2.1. Surface Receptors and Signaling Pathways

Over the past three decades, numerous studies have shown that *L. edodes*-derived polysaccharides exhibit immunomodulatory properties. It has been confirmed that they can modulate both innate and adaptive immune responses, and thus should be considered as biological response modifiers (BRMs) [9,10]. *L. edodes* biologically active polysaccharides mostly belong to the group of β-glucans. Glucans are PAMPs, therefore numerous cell surface receptors on monocytes/macrophages, neutrophils, natural killer (NK) cells, dendritic cells (DCs), as well as T and B cells recognize them [11,12]. So far, several polysaccharide-binding receptors have been identified, including complement receptor 3 (CR3), dectin-1, and lactosylceramide (LaCer). CR3 is expressed on neutrophils, monocytes, macrophages, and NK cells and recognizes mainly β-1,3-glucans [11]. The interaction of polysaccharides with CR3 leads to enhanced spleen tyrosine kinase (Syk) phosphorylation, augmented phosphorylidyinositol3 kinase (PI3K) activation, and stimulation of nuclear factor kappa B (NF-κB) leading to the cytokine production (including interleukin (IL)-2, IL-10, tumor necrosis factor (TNF)-α) [13]. Dectin-1 is expressed on monocytes, macrophages, neutrophils, T cells, and dendritic cells. It recognizes β-1,3- and β-1,6-glucans. Binding of β-glucans to dectin-1 activates numerous signaling pathways, including Syk, PI3K/protein kinase B (Akt), mitogen-activated protein kinase (MAPK), and nuclear factor of activated T
cells (NFAT), to enhance innate immune responses (phagocytosis, reactive oxygen species production, IL-12, IL-6, IL-10, and TNF-α synthesis) [12,13]. Lactosylceramide (LaCer) is another polysaccharide-binding receptor which recognizes β-1,3-glycans. LaCer is highly expressed on neutrophils, macrophages, and dendritic cells. The interaction of polysaccharides with LaCer enhances neutrophil oxidative burst response, induces macrophage inflammatory protein (MIP)-2, and activates NF-κB (via protein kinase C (PKC)-dependent pathway) [13,14]. It has been suggested that fungal β-glucans can also be recognized by scavenger receptors (expressed on macrophages and dendritic cells), however, the exact mechanism of their activation is not fully understood. It is believed that ligand binding is associated with activation of kinases PI3K/Akt and MAPK [15,16]. β-glucan receptors on immune cells and immune activation induced by β-glucans are presented in Figure 2.

![Figure 2. Main β-glucan receptors on immune cells and their immunomodulatory properties.](image)

Due to the fact that fungal polysaccharides from various sources have different composition, molecular weight, and conformation, they can bind to multiple receptor types with different affinity and activate various signalling pathways. Therefore, it is very likely that future research will contribute to the discovery of new receptors for mushroom-derived polysaccharides.

2.2. Immunomodulatory Properties of Polysaccharides from L. edodes—Studies Performed in Animals

Numerous studies have been conducted to determine the immunomodulatory effects of polysaccharides isolated from mycelium or fruiting bodies of L. edodes in animal models. Chen et al. [8] investigated immunomodulatory properties of three polysaccharide fractions (named F1, F2, and F3) isolated from L. edodes water extracts in BALB/c mice. All three fractions were composed of glucose (Glc), galactose (Gal), and mannose (Man) in different proportions. F1 was mainly composed of 38.0% Glc, 12.2% Gal, and 12.3% Man. F2 mainly consisted of 28% Glc, 4.6% Gal, and 4.4% Man; F3 contained 13.6% Glc, 2.7% Gal, and 2.5% Man. Moreover, all three fractions had different molecular weights (136 kDa, 14–61 kDa, and 14–35 kDa, respectively). The study demonstrated that F1, F2, and F3 polysaccharides increased thymus index and footpad thickness in mice. In addition, all
three fractions increased proliferation of Concanavalin A- and LPS-stimulated splenocytes. The group also revealed that F2 and F3 upregulated serum immunoglobulin (Ig) G and IgM levels and enhanced NK cells cytotoxicity. These results suggest that F1, F2, and F3 polysaccharides isolated from *L. edodes* had immunoenhancing activity. The fraction with the highest molecular weight (F1) improved cellular immunity, while F2 and F3 improved both cellular and humoral immunity.

In a study by Pan et al. [17], the effect of supplementation of *L. edodes*-derived 1,3/1,6-β glucan on C57BL/6j mice gut microbiota was evaluated. It was reported that both short-term (7 days) and long-term (15 weeks) supplementation of β-glucan (at the dose of 1.5 mg per mouse/day) inhibited macrophage accumulation in the colon of mice fed by a high-fat diet and downregulated the expression of proinflammatory cytokines, including IL-6, TNF-α, and IL-1β.

The immunomodulatory properties of bioprocessed polysaccharide (BPP) isolated from *L. edodes* liquid mycelial culture supplemented with black rice bran were studied by Kim and colleagues [18]. BPP is a β-glucan composed of glucose, galactose, rhamnose, fucose, mannose, and xylose. It was found that BPP upregulated spleen lymphocyte proliferation, as well as increased serum IFN-α levels in mice infected with *Salmonella Typhimurium*. In addition, BPP administration augmented Th1 cytokines production (including IL-1β, IL-2, IL-6, and IL-12) in mice splenocytes but did not affect Th2 cytokines production (IL-4, IL-5, and IL-10). The same polysaccharide, isolated from mycelial culture supplemented with tumeric reduced the phagocytic activity of the chicken-derived macrophage cell line HD-11 when infected with *Salmonella Gallinarum* and upregulated the expression of IL-1β, IL-10, TNF-α and inducible nitric oxide synthase in response to various *Salmonella* infections [19].

In another study, the biological activity of five novel polysaccharides (described as SLNT1, SLNT2, JLNT1, JLNT2, and JLNT3) isolated from the dried fruit body of *L. edodes* was evaluated in H22-bearing mice [20]. All polysaccharides consisted of glucose and had similar structures of (1→3)-linked-β-D-glucan and triple-helix conformation. Biological activity analyzes demonstrated that supplementation of two out of five tested polysaccharides with the highest molecular weights (SLNT1 and JLNT1) suppressed H22 tumor growth. Moreover, these two polysaccharides stimulated IL-2 and TNF-α production and induced the tumor cell apoptosis.

In a study by Song et al. [21], the biological effect of acidic-hydrolysis polysaccharides from spent mushroom compost of *L. edodes* (ASMCP) was evaluated in mice with LPS-induced kidney injury (KI). ASMCP is a homogenous β-glucan composed of rhamnose, (32.36%), arabinose (22.58%), galactose (8.92%), and glucose (36.14%), with molar ratios of 4:3:1:4. Immunological studies demonstrated that ASMCP reduced the serum levels of TNF-α, IL-6 and IL-1β, urea nitrogen, creatinine, and uric acid. Moreover, it upregulated activity of superoxide dismutase, catalase, and malondialdehyde, suggesting their antioxidant, antiinflammatory, and renoprotective activity.

In another study, the impact of lentinan, a (1→3)-β-glucan with (1→6) branches, encapsulated into CaCO₃ microParticles on lymphocyte activation, as well as humoral and cellular immunity in BALB/c mice, was analyzed [22]. Animals were immunized with ovalbumin (OVA) and injected with lentinan (0.2 mL at a concentration of 10 µg/mL). It was demonstrated that lentinan-CaCO₃-OVA enhanced lymphocyte proliferation, increased activation of B cells, and upregulated the ratio of CD4⁺ to CD8⁺ T cells in spleen lymphocytes. In addition, increased secretion of immunoglobulins IgG and IL-2, IL-4, IFN-γ, and TNF-α was observed.

In another similar research, lentinan was covalently attached to multiwalled carbon nanotubes (MWCNTs) and its immunoregulatory capacities were analyzed in BALB/c mice [23]. Hydrophobic MWCNTs in this study were used as an adjuvant in a vaccine delivery system for intensification of the immune response. The study demonstrated that lentinan attached to MWCNTs (L-MWCNTs) had higher solubility, lower cytotoxicity, and higher biostability than soluble lentinan. L-MWCNTs enhanced production of IL-4, IL-6,
TNF-α, and IFN-γ. Moreover L-MWCNTs upregulated the percentage of CD4+ and CD8+ T cells in the spleen and enhanced the production of anti-OVA IgG antibodies. The observed enhancement of the immunomodulatory effects of lentinan was associated with the fact that nanotubes rapidly entered immune cells, contained larger amounts of antigens, and potentiated cellular and humoral immunity.

Wang and colleagues [24] investigated the effect of lentinan on the immune cells of BALB/c mice with sepsis. Animals received 40, 100 or 250 mg/kg of lentinan daily (by intraperitoneal injection). It was found that the drug (at all doses tested) significantly decreased IL-10 production and FoxP3 expression by CD4+CD25+ Tregs. Moreover, it attenuated LPS-stimulated Erk–FoxO1 activation. The obtained results led to the hypothesis that lentinan could be used as an immunoregulatory drug preventing sepsis in patients with burns, however, further studies in this field are needed.

The immunomodulatory effects of orally administered lentinan were also studied in rainbow trout (Oncorhynchus mykiss) with LPS-induced inflammation [25]. It has been demonstrated that lentinan decreased the expression of TNF- and IFN-related genes involved in acute inflammatory reactions.

In another study, the impact of lentinan supplementation on immune response in Brown Norway rats was studied by McCormack et al. [26]. Lentinan (12 mg/kg) was orally administered for 20 weeks and the number of immune cells, as well as serum levels of GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, and TNF-α, was determined. It was found that lentinan supplementation increased the number of circulating monocytes and CD8+ T cells and decreased the ratio of CD4/CD8 cells. Moreover, this drug reduced the production of IL-4, IL-6, IL-10, and GM-CSF.

Zheng et al. [27] isolated and purified a polysaccharide, named L-II from the fruiting body of L. edodes, and evaluated its effects on the cellular immune response in Sarcoma-180-bearing mice. The polysaccharide L-II consisted of d-glucopyranose and had molecular weight of 2.03 × 10^5 Da. Animals were treated with L-II in doses 1, 5, and 10 mg/kg body weight. It was demonstrated that L-II in all tested concentrations increased the thymus and spleen weight, delayed-type hypersensitivity response, as well as the phagocytosis of macrophages. Moreover, this polysaccharide elevated serum TNF-α and IFN-γ but not IL-2. In addition, L-II increased nitrogen oxide production and catalase activity in macrophages.

Jeff et al. [28], likewise, isolated and purified two mannogalactoglucon-type polysaccharides (WPLE-N-2 and WPLE-A0.5-2), from the fruiting bodies of L. edodes, and evaluated their effects on the cellular immune response of Sarcoma-180-bearing mice. Both polysaccharides were α-glucans composed of glucose, galactose, and mannose. Animals were treated with 100 mg/kg body weight of the polysaccharides for 10 days. The group observed a significant tumor regression in the polysaccharides’ groups. Moreover, polysaccharides upregulated NO production in peritoneal macrophages and macrophage phagocytosis and enhanced concanavalin and LPS-induced splenocytes proliferation.

Park and colleagues [29] investigated whether a standardized mycelial extract of L. edodes, containing α- and β-glucans, amino acids, and minerals (named AHCC®) promotes the therapeutic effect of immunotherapy in cancers in mice. The group used a combination of oral AHCC® and dual immune checkpoint blockade (DICB), including PD-1/CTLA-4 blockade. It was demonstrated that the treatment reduced tumor growth and increased granzyme B and Ki-67 expression by tumor-infiltrating CD8+ T cells in MC38 colon-cancer-bearing mice compared with a combination of water and DICB.

All of the results, which are summarized in Table 1, suggest that polysaccharides isolated from L. edodes have immunomodulatory properties. However, different studies gave opposite results. Reasons for such divergences may be different animal models used in studies, different chemical structure and molecular weight of analyzed polysaccharides, or even lack of precise analysis of which of the components of the extracts/powdered L. edodes is responsible for the observed immunomodulatory activity. Therefore, future investigation in this field is needed.
Table 1. Main studies of immunomodulatory effects of *L. edodes* polysaccharides in animal models.

| Sample                                                                 | Animal Model                                      | Immunomodulatory Effects                                                                 | Reference   |
|------------------------------------------------------------------------|---------------------------------------------------|-----------------------------------------------------------------------------------------|-------------|
| F1, F2, and F3 heteropolysaccharide fractions composed of glucose,      | BALB/c mice                                       | 1. Increased thymus index and footpad thickness (F1, F2, and F3 fraction).             | Chen et al. [8] |
| galactose, and mannose in different proportions, isolated from *L. edodes* water extracts |                                                    | 2. Increased proliferation of Con A- and LPS-stimulated splenocytes (F1, F2, F3 fraction). |             |
|                                                                       |                                                    | 3. Increased serum IgG and IgM levels (F1, F2, F3 fraction).                           |             |
|                                                                       |                                                    | 4. Enhanced cytotoxic activity of NK cells (F2 and F3 fraction).                       |             |
| 1, 3/1, 6-β-glucan from *L. edodes*                                     | C57BL/6j mice                                     | 1. Inhibited macrophage accumulation in the colon.                                     | Pan et al. [17] |
| Bioprocessed polysaccharide (BPP)—β-glucan composed of glucose,        | BALB/c mice infected with *Salmonella Typhimurium* | 1. Upregulated spleen lymphocyte proliferation.                                        | Kim et al. [18] |
| galactose, rhamnose, fucose, mannose, and xylose, isolated from *L. edodes* liquid mycelial culture supplemented with black rice bran |                                                    | 2. Increased serum IFN-α levels.                                                      |             |
|                                                                       |                                                    | 3. Increased IL-1β, IL-2, IL-6, and IL-12 production in splenocytes.                   |             |
| Bioprocessed polysaccharide (BPP)—β-glucan composed of glucose,        | Chickens infected with *Salmonella Gallinarum*    | 1. Reduced phagocytic activity of the chicken-derived macrophage cell line HD-11.       | Han et al. [19] |
| galactose, rhamnose, fucose, mannose, and xylose, isolated from *L. edodes* liquid mycelial culture supplemented with tumeric |                                                    | 2. Increased expression of IL-1β, TNF-α, iNOS.                                        |             |
|                                                                       |                                                    | 3. Reduced expression of IL-4, IL-6, IFN-β, IFN-γ.                                     |             |
| SLNT1, SLNT2, JLNT1, JLNT2, and JLNT3 polysaccharides (1→3)-β-glucans  | H22-bearing mice                                   | 1. Suppressed H22 tumor growth and enhanced tumor cell apoptosis (SLNT1 and JLNT1).     | Wang et al. [20] |
| composed of glucose, isolated from *L. edodes* fruit body              |                                                    | 2. Increased IL-2 and TNF-α production (SLNT1 and JLNT1).                             |             |
| Polysaccharide (homogenous β-glucan composed of rhamnose, arabinose,   | Kunning strain mice with LPS-induced kidney injury | 1. Reduced the serum levels of TNF-α, IL-6 and IL-1β.                                   | Song et al. [21] |
| galactose, and glucose) isolated from *L. edodes* spent compost (ASMCP) |                                                    | 2. Reduced serum levels of urea nitrogen, creatinine, and uric acid.                   |             |
|                                                                       |                                                    | 3. Increased activity of superoxide dismutase, catalase, and malondialdehyde.         |             |
| Lentinan (1→3)-β-glucan with (1→6) branches encapsulated into CaCO3    | BALB/c mice                                       | 1. Enhanced lymphocyte proliferation.                                                  | Liu et al. [22] |
| microparticles                                                          |                                                    | 2. Enhanced activation of B cells.                                                    |             |
|                                                                       |                                                    | 3. Increased ratio of CD4+ to CD8+ T cells in spleen lymphocytes.                      |             |
|                                                                       |                                                    | 4. Increased serum IgG levels.                                                        |             |
|                                                                       |                                                    | 5. Increased IL-2, IL-4, IFN-γ, and TNF-α production.                                 |             |
| Lentinan covalently attached to multiwalled carbon nanotubes            | BALB/c mice                                       | 1. Enhanced production of antiviral IgG antibodies.                                   | Xing et al. [23] |
|                                                                       |                                                    | 2. Increased production of IL-4, IL-6, TNF-α, and IFN-γ.                               |             |
|                                                                       |                                                    | 3. Upregulated percentage of CD4+ and CD8+ T cells in spleen.                          |             |
| Lentinan                                                               | BALB/c mice                                       | 1. Decreased IL-10 production.                                                        | Wang et al. [24] |
|                                                                       |                                                    | 2. Decreased Fox3 expression of CD4+ CD25+ Tregs                                     |             |
|                                                                       |                                                    | 3. Decreased LPS-induced IL-10 production in Tregs.                                   |             |
|                                                                       |                                                    | 4. Attenuated LPS-stimulated Erk–FoxO1 activation.                                    |             |
| Lentinan                                                               | Rainbow trout (*Oncorhynchus mykiss*) with LPS-induced inflammation | 1. Decreased expression of TNF- and IFN-related genes.                               | Djordjevic et al. [25] |
| Lentinan                                                               |                                                    | 2. Increased production of IL-4, IL-6, TNF-α, and IFN-γ.                               |             |
|                                                                       |                                                    | 3. Upregulated percentage of CD4+ and CD8+ T cells in spleen.                          |             |
|                                                                       |                                                    | 4. Increased serum IgG levels.                                                        |             |
|                                                                       |                                                    | 5. Increased IL-2, IL-4, IFN-γ, and TNF-α production.                                 |             |
|                                                                       |                                                    | 6. Increased IL-1β.                                                                  |             |
Table 1. Cont.

| Sample                                               | Animal Model                  | Immunomodulatory Effects                                                                 | Reference |
|-------------------------------------------------------|-------------------------------|------------------------------------------------------------------------------------------|-----------|
| Lentinan                                              | Brown Norwegian rats          | 1. Increased number of circulating monocytes.                                              | Jeff et al. [26] |
|                                                       |                               | 2. Increased number of CD8\(^+\) T and decreased ratio of CD4/CD8 cells.                      |           |
|                                                       |                               | 3. Decreased production of IL-4, IL-6, IL-10, and GM-CSF.                                  |           |
| L-II polysaccharide consisted of D-glucopyranose, isolated from L. edodes fruiting body | Sarcoma 180-bearing mice     | 1. Increased the thymus and spleen weight.                                                 | Zheng et al. [27] |
|                                                       |                               | 2. Increased delayed-type hypersensitivity response.                                       |           |
|                                                       |                               | 3. Increased phagocytosis of macrophages.                                                  |           |
|                                                       |                               | 4. Increased TNF-\(\alpha\) and IFN-\(\gamma\) serum levels.                              |           |
|                                                       |                               | 5. Increased NO production and catalase activity in macrophages.                           |           |
| WPLE-N-2 and WPLE-A0.5-2 polysaccharides(\(\alpha\)-glucans composed of glucose, galactose, and mannose), isolated from L. edodes fruiting body | Sarcoma 180-bearing mice | 1. Increased NO production in peritoneal macrophages.                                     | Jeff et al. [28] |
|                                                       |                               | 2. Increased phagocytosis of macrophages.                                                  |           |
|                                                       |                               | 3. Enhanced Con-A and LPS-induced splenocytes proliferation.                               |           |
| AHCC\(^\circledR\), a standardized extract of cultured L. edodes mycelia containing \(\alpha\)- and \(\beta\)-glucans, starches, sugars, amino acids, and minerals | C57BL/6 mice                 | 1. Reduced tumor growth.                                                                  | Park et al. [29] |
|                                                       |                               | 2. Increased granzyme B and Ki-67 expression by tumor-infiltrating CD8\(^+\) T cells.    |           |

Abbreviations: Con-A, concanavalin A; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; NK, natural killer; NO, nitrogen oxide; LPS, lipopolysaccharide; TNF, tumor necrosis factor.

2.3. Immunomodulatory Properties of Polysaccharides from L. edodes—Studies Performed in Humans

The first studies on the biological activity of L. edodes polysaccharides in humans were carried out in the 1980s. The immune activating effects of lentinan were firstly described in healthy humans by Aoki [30] and Tani et al. [31]. It was found that this drug in vitro enhanced the proliferation of peripheral blood mononuclear cells (PBMCs) and increased the production of lymphokine-activated killer cell and NK cells activity. Similar results were obtained in gastric cancer patients when lentinan was administered intravenously (2 mg of lentinan for 7 days) with classic chemiotherapy [31,32]. Moreover, it was found that this drug significantly increased IL-1\(\alpha\), IL-1\(\beta\), and TNF-\(\alpha\) production by PBMCs of these patients, and increased the ratio of activated T cells and cytotoxic T cells in the spleen [30,32]. In another study, conducted in patients with gastric cancer the effect of lentinan on lymphocyte subsets of peripheral blood, lymph nodes, and tumor tissues was evaluated [33]. A total of 2 mg of lentinan was intravenously administered twice to twelve patients. No changes in the lymphocyte subsets of peripheral blood were found, however, the number of CD4\(^+\) T cells in lymph nodes was elevated. In addition, the number of tumor-infiltrating CD4\(^+\), Leu11, and LeuM3 cells was significantly increased.

The effect of orally administered lentinan on the immune response in healthy elderly humans was investigated in the placebo-controlled clinical study in 2011 [34]. Forty-two participants were randomly assigned to two groups given either 2.5 mg/day Lentinex\(^\circledR\) or placebo. It was found that the number of total CD3\(^+\) T cells and CD4\(^+\) T cells was lower in the placebo group than in the Lentinex\(^\circledR\) group, however, no changes in the number of CD8\(^+\) T cells were detected. In addition, it was demonstrated that the number of B cells in the placebo group was nonsignificantly decreased and nonsignificantly increased in the Lentinex\(^\circledR\) group. Interestingly, the difference between groups after six weeks after the end of the supplementation was significant. The number of CD56\(^+\) NK cells increased significantly in both groups, but there was no difference between the groups. Changes in humoral response were also described. The complement C3 decreased significantly in both groups, but no difference between the groups was observed. No statistically significant changes in IgG, IgA, and IgM levels were found between the studied groups.
In another randomized, placebo-controlled clinical trial, the hypocholesterolemic, microbiota-modulatory, and immunomodulatory effect of L. edodes extract was analyzed in hypercholesterolemic patients [35]. Fifty-two participants were assigned to two groups given either a β-D-glucan-enriched (BGE) mixture (10.4 g/day) obtained from L. edodes fruiting bodies ensuring a 3.5 g/day of fungal β-D-glucans or a placebo incorporated in three different food products. No significant differences in lipid- or cholesterol-related parameters were found compared with the placebo group. In addition, the BGE showed no immunomodulatory effect (including changes in IL-1β, IL-6, and TNF-α production). However, BGE modulated the colonic microbiota.

The immunomodulating properties of L. edodes mushroom have also been investigated in healthy young adults in another randomized study [36]. Fifty-two participants were randomized to consume either one (5 g) or two (10 g) servings of dried, prepared L. edodes daily for 4 weeks. It was demonstrated that mushrooms consuming increased ex vivo proliferation of γδ-T cells and NK-T cells, as well as the expression of activation receptors on these cells. In addition, an increased level of secretory IgA in saliva and decreased level of C-reactive protein in serum was observed. The concentration of IL-1α, IL-1β, IL-4, IL-6, IL-10, IL-17, IFN-γ, TNF-α, macrophage inflammatory protein-1α/chemokine C-C ligand 3 (MIP-1α/CCL3), and MIP-1β in PBMCs culture supernatants was also analyzed. It was found that mushroom intake upregulated IL-4, IL-10, TNF-α, and IL-1α levels and downregulated MIP-1α/CCL3. No changes were observed for IL-6, IL-1β, MIP-1β, IL-17, and IFN-γ. It was concluded that regular L. edodes consumption resulted in improved immunity, however, it was not analyzed which component of the mushroom exerted immunomodulatory effects.

Wang et al. [37] evaluated the influence of lentinan on cytokines profile and T cell subsets in 73 patients with nonsmall cell lung cancer (NSCLC) treated with vinorelbin and cisplatin. As expected, all patients with NSCLC had a higher subset ratio of CD3+CD8+ T cells. It was found that the combined therapy of lentinan–vinorelbin–cisplatin resulted in a significant increase in CD3+CD56+NKT cells, CD3+CD8+, and CD3+CD4+ subsets. Moreover, therapy with lentinan decreased the number of CD4+CD25+ Tregs, increased the production of IL-10 and TGF-β1, and upregulated IFN-γ, TNF-α, and IL-12. It was concluded that lentinan-based chemo-immunotherapy could be a promising strategy in NSCLC treatment.

Our group also investigated the immunomodulatory properties of polysaccharides from L. edodes in healthy human immune cells. We isolated from the mycelial cultures a selenium(Se)-enriched analog of lentinan (named Se-L) and, as a reference, the non-Se-enriched fraction (named L) and evaluated its effects on the proliferation of human PBMCs stimulated with various T and B-cells mitogens and influence on superoxide anions (O2−) production by granulocytes [38]. Our study demonstrated that none of the polysaccharides has a significant effect on the generation of reactive oxygen species by granulocytes. However, we found that both fractions significantly decreased the proliferation of PBMCs stimulated with anti-CD3 antibody and phytohemagglutinin (PHA) in a dose-dependent manner. Structural studies of the obtained fraction revealed that it is a protein-containing mixture of high molar mass polysaccharides (MW 3.9 × 10^6 g/mol and 2.6 × 10^5 g/mol) α- and β-glucans composed of glucose or mannose. At this early stage of the research, it was not determined which of the components of the fraction was responsible for the immunosuppressive activity. Therefore, in our next study, we separated homogenous (Se)-enriched fraction (named Se-Le-30), defined four-polysaccharide components of this fraction, and determined their structures and immunomodulatory properties in human immune cells [39,40]. We found that Se-Le-30 downregulated the proliferation of human PBMCs stimulated with anti-CD3 antibodies or allostimulated and decreased the production of TNF-α by CD3+ T cells. This result suggests that Se-Le-30 fraction is a selective T cells immunosuppressant, which presumably acts through the modulation of signaling via the TCR-CD3 receptor complex. Later analyses demonstrated that all four polysaccharide components of Se-Le-30 also inhibited the proliferation of anti-CD3-stimulated PBMCs,
but the inhibitory effect was weaker than that of the Se-Le-30 fraction. In continuation of our study, we extracted from a postculture medium of *L. edodes* exopolysaccharides fraction (Se-containing and nonselenated) composed mainly of a highly branched 1-6-α-mannoprotein of molecular weight $4.5 \times 10^6$ Da and also evaluated its effect on human PBMCs and granulocytes. The analysis demonstrated that similarly to polysaccharides isolated from *L. edodes* mycelium, exopolysaccharides have no influence on the production of reactive oxygen species by granulocytes but reduce PMBCs proliferation induced by the anti-CD3 antibody. However, the observed effect was much weaker than that for the fractions isolated from mycelium [41].

Most of the results (summarized in Table 2) strongly suggest that polysaccharides from *L. edodes* have immunomodulatory properties in humans, however, various polysaccharide fractions may significantly differ in biological activity. These differences result both from the polysaccharides source (fruits bodies or mycelium) and extraction method, which affects monosaccharide composition, molecular weight, branching degrees, and helical conformation [7,8]. Lentinan, a (1→3)-β-glucan with (1→6) branches, extracted from fruiting bodies of *L. edodes*, functions as an effective immunostimulatory agent. In contrast, polysaccharides with different structure isolated from *L. edodes* mycelium have selective immunosuppressive activity.

Table 2. Main studies of immunomodulatory effects of *L. edodes* polysaccharides in humans.

| Sample                                                                 | Participants                      | Immunomodulatory Effects                                                                 | Reference  |
|-----------------------------------------------------------------------|-----------------------------------|-----------------------------------------------------------------------------------------|------------|
| Lentinan used in PBMCs culture                                       | Healthy humans                    | 1. Enhanced proliferation of PBMCs.                                                     | Aoki [30]  |
|                                                                       |                                   | 2. Increased production of lymphokine-activated killer cell.                             | Tani et al. [31] |
|                                                                       |                                   | 3. Increased NK cells activity.                                                          |            |
| Lentinan administered intravenously with chemotherapy                | Gastric cancer patients           | 1. Enhanced proliferation of PBMCs.                                                     | Tani et al. [31] |
|                                                                       |                                   | 2. Increased production of lymphokine-activated killer cell.                             | Arinaga et al. [32] |
|                                                                       |                                   | 3. Increased NK cells activity.                                                          | Takeshita et al. [33] |
|                                                                       |                                   | 4. Increased IL-1α, IL-1β, and TNF-α production by PBMCs.                               |            |
|                                                                       |                                   | 5. Increased ratio of activated T cells and cytotoxic T cells in the spleen.             |            |
|                                                                       |                                   | 6. Elevated number of CD4 cells in lymph nodes                                           |            |
|                                                                       |                                   | 7. Increased number of tumor-infiltrating CD4, Leu11, and LeuM3 cells.                  |            |
| Lentinan administered orally                                          | Healthy elderly humans            | 1. Higher number of total CD3$^+$ and CD4$^+$ T cells.                                   | Gaulier et al. [34] |
|                                                                       |                                   | 2. Increased number of B cells (nonsignificantly).                                      |            |
| β-D-glucan-enriched mixture obtained from *L. edodes* fruiting bodies | Patients with hypercholesterolemia| 1. No changes in IL-1β, IL-6, and TNF-α production.                                     | Morales et al. [35] |
| incorporated in food products                                         |                                   | 2. Increased expression of activation receptors on γδ-T cells.                          |            |
|                                                                       |                                   | 3. Increased level of secretory IgA in saliva.                                           |            |
|                                                                       |                                   | 4. Decreased level of CRP in serum.                                                     |            |
| Whole dried *L. edodes*                                               | Healthy young humans              | 3. Increased level of secretory IgA in saliva.                                           | Dai et al. [36] |
|                                                                       |                                   | 4. Decreased level of CRP in serum.                                                     |            |
|                                                                       |                                   | 5. Upregulated production of IL-4, IL-10, TNF-α, and IL-1α by PBMCs.                   |            |
|                                                                       |                                   | 6. Downregulated production of MIP-1α/CCL3 by PBMCs.                                    |            |
| Lentinan in combined therapy with vinorelbain and cisplatin          | Patients with non-small cell lung cancer (NSCLC) | 1. Increased number of CD3$^+$CD56$^+$ NKT cells.                                      | Wang et al. [37] |
|                                                                       |                                   | 2. Increased number of CD3$^+$CD8$^+$ T cells.                                          |            |
|                                                                       |                                   | 3. Increased number of CD3$^+$CD4$^+$ T cells.                                         |            |
|                                                                       |                                   | 4. Decreased number of CD4$^+$CD25$^+$ Tregs.                                       |            |
|                                                                       |                                   | 5. Increased production of IL-10, TGF-β1, IFN-γ, TNF-α, and IL-12.                      |            |
3. Polysaccharides from L. edodes as Vaccine Adjuvants

A separate area of research is the analysis on the use of L. edodes polysaccharides as vaccine adjuvants in order to increase the immunogenicity of antigens [42]. It has been proven that polysaccharides of natural origin are safe, nontoxic, have good biocompatibility, and are able to stimulate the immune response alone [43].

Lentinan as a biologically active polysaccharide was investigated as a potential adjuvant for Bacillus Calmette–Guérin (BCG) vaccination [44]. Drandarska and colleagues studied the immunomodulating effects of the combined application of BCG with lentinan (intranasal application at a dose of 1 mg/kg, three times at 2-day intervals) in guinea pigs. Forty-five days after treatment, H2O2 and nitrite production by alveolar macrophages, as well as their killing ability against Mycobacterium tuberculosis and Staphylococcus aureus, were measured. The obtained results suggest that BCG plus lentinan application induced a higher level of alveolar macrophage activation and enhanced the local immunohistological response to BCG in lungs.

In another study, it was suggested that lentinan enhanced the effects of the vaccine against Trichinella spiralis in C57BL/6 mice [45]. Recombinant T. spiralis Serpin (rTs-Serpin) was used as a vaccine with lentinan as an adjuvant. It was demonstrated that this combination reduced the rate of helminth burden, increased the levels of anti-rTs-serpin IgG1 and IgG2a antibodies, and upregulated production of IFN-γ and IL-4 by CD4+ T cells. Moreover, the group investigated the role of NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) in vaccine + lentinan-induced immune protection and found that lentinan increased the expression of NLRP3 mRNA, suggesting that this transcription factor may play a role in lentinan-induced immunoprotection.

Since only few studies have been conducted to analyze the potential of lentinan to influence vaccine effectiveness, further research is urgently needed. When testing new polysaccharides as vaccine adjuvants, it is important to take into consideration their separation methods, structure, and purity.

4. Concluding Remarks and Future Perspectives

In the last three decades, the immunomodulatory effects of various polysaccharides from L. edodes have been described. As summarized in the present review, numerous in vitro and in vivo studies conducted on animal models and in humans suggested that these glucans can be used as immunostimulants or immunosuppressants in many conditions.

Research confirms that L. edodes polysaccharides can modulate an immune response by various biochemical pathways, however, some analyses gave inconclusive or conflic-
ing results. Reasons for such divergences may be the presence of many variables that affect studies effects, including different L. edodes strains used, different cultivation conditions, various isolation and purification methods, as well as different dosage and route of administration.

Therefore, future studies must be focused not only on understanding the immune-related pathways and mechanisms but also on an improvement in the methodological quality.

**Author Contributions:** Conceptualization, A.R. and B.K.; writing—original draft preparation, A.R. and B.K.; writing—review and editing, J.T. and R.Z. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author without any restrictions.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Gaitán-Hernández, R.; López-Peña, D.; Esqueda, M.; Gutiérrez, A. Review of Bioactive Molecules Production, Biomass, and Basidiomata of Shiitake Culinary-Medicinal Mushrooms, Lentinus edodes (Agaricomycetes). *Int. J. Med. Mushrooms* 2019, 21, 841–850. [CrossRef]

2. Muszyńska, B.; Pazdur, P.; Lazur, J.; Sulkowska-Ziaja, K. *Lentinula edodes* (Shiitake)—Biological activity. *Med. Int. Rev.* 2017, 27, 189–195.

3. Bisen, P.S.; Baghel, R.K.; Sanodiya, B.S.; Thakur, G.S.; Prasad, G.B. *Lentinus edodes*: A macrofungus with pharmacological activities. *Curr. Med. Chem.* 2010, 17, 2419–2430. [CrossRef] [PubMed]

4. Finimundy, T.; Dillon, A.; Henriques, J.; Ely, M. A Review on General Nutritional Compounds and Pharmacological Properties of the *Lentinula edodes* Mushroom. *Food Nutr. Sci.* 2014, 5, 1095–1105.

5. Xu, X.; Yan, H.; Tang, J.; Chen, J.; Zhang, X. Polysaccharides in *Lentinus edodes*: Isolation, structure, immunomodulating activity and future prospective. *Crit. Rev. Food Sci. Nutr.* 2014, 54, 474–487. [CrossRef]

6. Sheng, K.; Wang, C.; Chen, B.; Kang, M.; Wang, M.; Liu, K.; Wang, M. Recent advances in polysaccharides from *Lentinus edodes* (Berk.): Isolation, structures and bioactivities. *Carbohydr. Res.* 2021, 424, 30–41. [CrossRef] [PubMed]

7. Meng, X.; Liang, H.; Luo, L. Antitumor polysaccharides from mushrooms: A review on the structural characteristics, antitumor mechanisms and immunomodulating activities. *Carbohydr. Res.* 2016, 424, 30–41. [CrossRef] [PubMed]

8. Chen, S.; Liu, C.; Huang, X.; Hu, L.; Huang, Y.; Chen, H.; Fang, Q.; Dong, N.; Li, M.; Tang, W.; et al. Comparison of immunomodulatory effects of three polysaccharide fractions from *Lentinula edodes* water extracts. *J. Funct. Foods* 2020, 66, 103791. [CrossRef]

9. Friedman, M. Mushroom Polysaccharides: Chemistry and Antiobesity, Antidiabetes, Anticancer, and Antibiotic Properties in Cells, Rodents, and Humans. *Foods* 2016, 5, 80. [CrossRef] [PubMed]

10. Leung, M.Y.; Liu, C.; Koon, J.C.; Fung, K.P. Polysaccharide biological response modifiers. *Immunol. Lett.* 2006, 105, 101–114. [CrossRef] [PubMed]

11. Akramiene, D.; Kondrotas, A.; Didziapetriene, J.; Kevelaitis, E. Effects of beta-glucans on the immune system. *Medicina* 2007, 43, 597–606. [CrossRef] [PubMed]

12. Goodridge, H.S.; Wolf, A.J.; Underhill, D.M. Beta-glucan recognition by the innate immune system. *Immunol. Rev.* 2009, 230, 38–50. [CrossRef] [PubMed]

13. Chan, G.C.F.; Chan, W.K.; Sze, D.M.Y. The effects of beta-glucan on human immune and cancer cells. *J. Hematol. Oncol.* 2009, 2, 25. [CrossRef]

14. Zimmerman, J.W.; Lindermuth, J.; Fish, P.A.; Palace, G.P.; Stevenson, T.T.; DeMong, D.E. A novel carbohydrate-glycosphingolipid interaction between a beta-(1->3)-beta-D-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes. *J. Biol. Chem.* 1998, 273, 22014–22020. [CrossRef]

15. Rice, P.J.; Kelley, J.L.; Kogan, G.; Ensley, H.E.; Kalbfleisch, J.H.; Browder, I.W.; Williams, D.L. Human monocyte scavenger receptors are pattern recognition receptors for (1->3)-beta-D-glucans. *J. Leukoc. Biol.* 2002, 72, 140–146.

16. Lin, Y.L.; Liang, Y.C.; Lee, S.S.; Chiang, B.L. Polysaccharide purified from *Ganoderma lucidum* induced activation and maturation of human monocyte-derived dendritic cells by NF-kappa B and p38 mitogen-activated protein kinase pathways. *J. Leukoc. Biol.* 2005, 78, 533–543. [CrossRef]
17. Pan, W.; Jiang, P.; Zhao, J.; Shi, H.; Zhang, P.; Yang, X.; Biazik, J.; Hu, M.; Hua, H.; Ge, X.; et al. β-Glucan from *Lentinula edodes* prevents cognitive impairments in high-fat diet-induced obese mice: Involvement of colon-brain axis. *J. Transl. Med.* 2021, 19, 54. [CrossRef] [PubMed]

18. Kim, S.P.; Park, S.O.; Lee, S.J.; Nam, S.H.; Friedman, M. A Polysaccharide isolated from the liquid culture of *Lentinus edodes* (Shiitake) mushroom mycelia containing black rice bran protects mice against salmonellosis through upregulation of the Th1 immune reaction. *J. Agric. Food Chem.* 2014, 62, 2384–2391. [CrossRef]

19. Han, D.; Lee, H.T.; Lee, J.B.; Kim, Y.; Lee, S.J.; Yoon, J.W. A Bioprocessed Polysaccharide from *Lentinus edodes* Mycelia Cultures with Turmeric Promotes Chicks from a Lethal Challenge of *Salmonella Gallinarum*. *J. Food Prot.* 2017, 80, 245–250. [CrossRef]

20. Wang, K.P.; Zhang, Q.L.; Liu, Y.; Wang, J.; Cheng, Y.; Zhang, Y. Structure and inducing tumor cell apoptosis activity of polysaccharides isolated from *Lentinus edodes*. *J. Agric. Food Chem.* 2013, 61, 9849–9858. [CrossRef] [PubMed]

21. Song, X.; Ren, Z.; Wang, X.; Jia, L.; Zhang, C. Antioxidant, anti-inflammatory and renoprotective effects of acidic-hydrolytic polysaccharides by spent mushroom compost (*Lentinus edodes*) on LPS-induced kidney injury. *Int. J. Biol. Macromol.* 2020, 151, 1267–1276. [CrossRef]

22. Liu, Z.; Yu, L.; Gu, P.; Bo, R.; Wusiman, A.; Liu, J.; Hu, Y.; Wang, D. Preparation of lentinan-calcium carbonate microspheres and their application as vaccine adjuvants. *Carbohydr. Polym.* 2020, 245, 116520. [CrossRef]

23. Xing, J.; Liu, Z.; Huang, Y.; Qin, T.; Bo, R.; Zheng, S.; Luo, L.; Huang, Y.; Niu, Y.; Wang, D. Lentinan-Modified Carbon Nanotubes as an Antigen Delivery System Modulate Immune Response in Vitro and in Vivo. *ACS Appl. Mater. Interfaces* 2016, 8, 19276–19283. [CrossRef]

24. Wang, S.X.; Liu, Q.Y.; Li, Y. Lentinan ameliorates burn sepsis by attenuating CD4+ CD25+ Tregs. *Burns* 2016, 42, 1513–1521. [CrossRef]

25. Djordjevic, B.; Skugor, S.; Jørgensen, S.M.; Overland, M.; Mydland, L.T.; Krasnov, A. Modulation of splenic immune responses to bacterial lipopolysaccharide in rainbow trout (*Oncorhynchus mykiss*) fed lentinan, a beta-glucan from mushroom *Lentinula edodes*. *Fish Shellfish Immunol.* 2009, 26, 201–209. [CrossRef]

26. McCormack, E.; Skavland, J.; Mujic, M.; Bruserud, Ø.; Gjertsen, B.T. Lentinan: Hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia. *Nutr. Cancer* 2010, 62, 574–583. [CrossRef]

27. Zheng, R.; Jie, S.; Hanchuan, D.; Moucheng, W. Characterization and immunomodulating activities of polysaccharide from *Lentinus edodes*. *Int. Immunopharmacol.* 2005, 5, 811–820. [CrossRef]

28. Jeff, I.B.; Fan, E.; Tian, M.; Song, C.; Yan, J.; Zhou, Y. In vivo anticancer and immunomodulating activities of manngalactoglu- can-type polysaccharides from *Lentinus edodes* (Berkeley) Singer. *Cent. Eur. J. Immunol.* 2016, 41, 47–53. [CrossRef]

29. Park, H.J.; Boo, S.; Park, I.; Shin, M.S.; Takahashi, T.; Takanari, J.; Homma, K.; Kang, I. AHCC®, a Standardized Extract of Cultured *Lentinula edodes* Mycelia, Promotes the Anti-Tumor Effect of Dual Immune Checkpoint Blockade Effect in Murine Colon Cancer. *Front. Immunol.* 2022, 13, 875872. [CrossRef]

30. Aoki, T. Lentinan. In *Immune Modulation Agents and Their Mechanisms*; Fenichel, R.L., Chirigis, M.I., Eds.; Marcel Dekker: New York, NY, USA, 1984; pp. 63–77.

31. Tani, M.; Tanimura, H.; Yamaue, H.; Tsunoda, T.; Iwahashi, M.; Tama, M.; Hotta, T.; Mizobata, S. Augmentation of lymphokine-activated killer cell activity by lentinan. *Anticancer Res.* 1993, 13, 1773–1776.

32. Arinaga, S.; Karimine, N.; Takamuku, K.; Nanbara, S.; Inoue, H.; Nagamatsu, M.; Ueo, H.; Akiyoshi, T. Enhanced induction of lymphokine-activated killer activity after lentinan administration in patients with gastric carcinoma. *Int. J. Immunopharmacol.* 1992, 14, 535–539. [CrossRef]

33. Takeshita, K.; Watanuki, S.; Iida, M.; Saito, N.; Maruyama, M.; Sunagawa, M.; Habu, H.; Endo, M. Effect of lentinan on lymphocyte subsets of peripheral blood, lymph nodes, and tumor tissues in patients with gastric cancer. *Surg. Today* 1993, 23, 125–129. [CrossRef]

34. Gaullier, J.M.; Sleboda, J.; Øjfjord, E.S.; Ulvestad, E.; Nurmineni, M.; Moe, C.; Tor, A.; Gudmundson, O. Supplementation with a soluble β-glucan from *Shiitake* medicinal mushroom, *Lentinus edodes* (Berk.) singer mycelium: A crossover, placebo-controlled study in healthy elderly. *Int. J. Med. Mushrooms* 2011, 13, 319–326. [CrossRef]

35. Morales, D.; Shetty, S.A.; López-Plaza, B.; Gómez-Candela, S.; Smidt, H.; Marin, F.R.; Soler-Rivas, C. Modulation of human intestinal microbiota in a clinical trial by consumption of a β-D-glucan-enriched extract obtained from *Lentinula edodes*. *Eur. J. Nutr.* 2021, 60, 3249–3265. [CrossRef]

36. Dai, X.; Stanilka, J.M.; Rowe, C.A.; Esteves, E.A.; Nievesm, C.; Jr.; Spaisalr, S.J.; Christman, M.C.; Langkamp-Henken, B.; Percival, S.S. Consuming *Lentinula edodes* (Shiitake) Mushrooms Daily Improves Human Immunity: A Randomized Dietary Intervention in Healthy Young Adults. *J. Am. Coll. Nutr.* 2015, 34, 478–487. [CrossRef]

37. Wang, X.E.; Wang, Y.H.; Zhou, Q.; Peng, M.; Zhang, J.; Chen MMA, L.J.; Xie, G.M. Immunomodulatory Effect of Lentinan on Aberrant T Subsets and Cytokines Profile in Non-small Cell Lung Cancer Patients. *Pathiol. Oncol. Res.* 2018, 26, 499–505. [CrossRef]

38. Kaleta, B.; Górski, A.; Zagóźdżon, R.; Ciesiak, M.; Kazimierzczak-Barańska, J.; Nawrot, B.; Klimaszewska, M.; Malinowska, E.; Górski, S.; Turło, J. Selenium-containing polysaccharides from *Lentinula edodes*-Biological activity. *Carbohydr. Polym.* 2019, 223, 115078. [CrossRef] [PubMed]

39. Klimaszewska, M.; Górski, S.; Lapenias, G.; Kaleta, B.; Górski, S.; Kaszowska, M.; Dawidowski, M.; Gamian, A.; Zagóźdżon, R.; Górski, A.; et al. Identification of the Primary Structure of Selenium-Containing Polysaccharides Selectively Inhibiting T-Cell Proliferation. *Molecules* 2021, 26, 5404. [CrossRef]
40. Kaleta, B.; Roszczyk, A.; Zych, M.; Kniotek, M.; Zagoźdźon, R.; Klimaszewska, M.; Malinowska, E.; Pac, M.; Turło, J. Selective Biological Effects of Selenium-Enriched Polysaccharide (Se-Le-30) Isolated from *Lentinula edodes* Mycelium on Human Immune Cells. *Biomolecules* 2021, 11, 1777. [CrossRef]

41. Górska-Jakubowska, S.; Klimaszewska, M.; Podsadni, P.; Kaleta, B.; Zagoźdźon, R.; Górska, S.; Gamian, A.; Strączek, T.; Kapusta, C.; Cieslak, M.; et al. Selenium-Containing Exopolysaccharides Isolated from the Culture Medium of *Lentinula edodes*: Structure and Biological Activity. *Int. J. Mol. Sci.* 2021, 22, 13039. [CrossRef]

42. Shah, R.R.; Hassett, K.J.; Brito, L.A. Overview of Vaccine Adjuvants: Introduction, History, and Current Status. *Methods Mol Biol.* 2017, 1494, 1–13. [PubMed]

43. Wan, X.; Yin, Y.; Zhou, C.; Hou, L.; Cui, Q.; Zhang, X.; Cai, X.; Wang, Y.; Wang, L.; Tian, J. Polysaccharides derived from Chinese medicinal herbs: A promising choice of vaccine adjuvants. *Carboh. Polym.* 2022, 276, 2022. [CrossRef]

44. Drandarska, I.; Kussovski, V.; Nikolaeva, S.; Markova, N. Combined immunomodulating effects of BCG and lentinan after intranasal application in guinea pigs. *Int. Immunopharmacol.* 2005, 5, 795–803. [CrossRef]

45. Jin, X.; Liu, X.; Ding, J.; Zhang, L.; Yang, Y.; Wang, X.; Yang, Y.; Liu, M. Lentinan improved the efficacy of vaccine against *Trichinella spiralis* in an NLRP3 dependent manner. *PLoS Negl. Trop. Dis.* 2020, 14, e0008632. [CrossRef] [PubMed]